Resources from the same session
Introduction and background of locally advanced and metastatic urothelial cancer
Presenter: Ignacio Duran
Session: ESMO Colloquium supported by Astellas - Locally advanced and metastatic urothelial cancer (UC): State-of-the-art management in the new continuum of care
Resources:
Slides
Webcast
Optimal definition of patient populations: Platinum eligibility and biology-informed science
Presenter: Thomas Powles
Session: ESMO Colloquium supported by Astellas - Locally advanced and metastatic urothelial cancer (UC): State-of-the-art management in the new continuum of care
Resources:
Slides
Webcast
Continuum of care after progression on first-line therapy: Testing and rationalising
Presenter: Ignacio Duran
Session: ESMO Colloquium supported by Astellas - Locally advanced and metastatic urothelial cancer (UC): State-of-the-art management in the new continuum of care
Resources:
Slides
Webcast
Optimal management of ADC toxicities in patients with urothelial malignancies
Presenter: Andrew Weickhardt
Session: ESMO Colloquium supported by Astellas - Locally advanced and metastatic urothelial cancer (UC): State-of-the-art management in the new continuum of care
Resources:
Slides
Webcast
Case presentation of a patient with metastatic urothelial cancer: Criteria for choosing the right regimens in first-line and second-line locally advanced and metastatic urothelial cancer
Presenter: Eun Hee Jung
Session: ESMO Colloquium supported by Astellas - Locally advanced and metastatic urothelial cancer (UC): State-of-the-art management in the new continuum of care
Resources:
Slides
Webcast
Panel discussion
Session: ESMO Colloquium supported by Astellas - Locally advanced and metastatic urothelial cancer (UC): State-of-the-art management in the new continuum of care
Resources:
Webcast